

SYLLABUS

Course title and number: MSCI 689: Special topics in starting a biotechnology company

Term: Fall 2020

Meeting times and Aug 25 – Nov 3; Tuesdays, 2:00 – 5:00 pm, Virtual by Zoom

location:

Course Description and Prerequisites

The Special topics in starting a biotechnology company course will introduce graduate students to the fundamentals of starting a biotechnology company. The course will provide a framework for evaluating a business idea and outline the considerations that go into starting a biotechnology company.

This is a 10 week graded course worth 2 credit hours.

Prerequisites: Graduate student classification

Learning Outcomes or Course Objectives

After attending the course, graduate students should know the fundamentals of starting a biotechnology company. Graduate students are expected to have a basic understanding of: 1) how to recognize a business idea, 2) what is a business plan,3) rationale for developing an intellectual property strategy, 4) how to legally form a company, 5) have awareness of funding opportunities for a startup company, 6) regulatory pathways and 7) clinical trial strategy.

Specific learning outcomes for each lecture and team-based learning activities are listed in the course schedule below.

Instructor Information

Name Magnus Hook
Telephone number 713-677-7551
Email address mhook@tamu.edu
Office hours By appointment
Office location Available via Zoom

Textbook and/or Resource Material

There are no required textbooks for the course. If assigned reading is required for a topic, the instructor will provide the reading material prior to the date of the instructional activity as listed in the course schedule.

Grading Policies

Team assignments, team presentations and quizzes will contribute to the student's final course grade.

The course grade consists of weighted contributions from a student's scores from the following scored elements:

| Scored Element | Weighted contribution to course grade | | | |
|--------------------------------|---------------------------------------|--|--|--|
| 4 Team Assignments (take-home) | 30% (7.5% each) | | | |

| 2 Quizzes | 20% (10% each) |
|-------------------------|----------------|
| Final Team presentation | 50% |
| Total | 100% |

Grading Scale

Grading Scale for the course:

A = 90-100%

B = 80-89%

C = 70-79%

D = 60-69%

F = <60%

Attendance / Make-up Work Policies

Attendance in this course is required since there are only 10 classes in 10 weeks. An excused absence must be requested and approved by the instructor in advance. In accordance with Texas A&M attendance and make-up policies, please refer to the website link to Student Rule 7 at http://student-rules.tamu.edu/rule07

Late submission of an assignment or quiz is not allowed. A quiz or assignment that is not submitted before the due date receives a grade of zero. The only exception arises when a student has an excused absence. University attendance requirements, make up policies and rules related to excused/unexcused absences are located on-line at http://student-rules.tamu.edu/rule07

Course Topics, Calendar of Activities, Major Assignment Dates

| Block | Topic | Time | Date | Instructor | Learning Outcomes | Assignments |
|--------|-----------------|--------|----------|---------------------|------------------------|-------------|
| Number | | | | | | Due/Quizzes |
| A | Opportunity | 1 hour | 08/25/20 | Rick Silva, Ph.D., | 1. Explain opportunity | None |
| L | recognition: | | | MBA | recognition steps and | |
| | Needs | | | Executive Director | the role of needs | |
| | assessment | | | Clinical | assessment in | |
| | | | | Translational | evaluating a company | |
| | | | | Industry | idea | |
| | | | | Collaborations, | 2. Differentiate | |
| | | | | Texas A&M Health | between a product | |
| | | | | Science Center | and a company | |
| | | | | | 3. Describe target | |
| | | | | | product profile | |
| | Team based | 2 | | | Teams will be | |
| | learning | hours | | | expected to develop | |
| | | | | | target product profile | |
| 4 | Opportunity | 1 hour | 09/01/20 | Omar Hakim, M.S. | 1. Explain market | Team |
| 1 | recognition: | | | Professor of | landscape, market | assignment |
| _ | Market analysis | | | Practice | segmentation and | 1: Target |
| | | | | (Entrepreneurship | target market | product |
| | | | | & Technology | 2. Differentiate total | profile |
| | | | | Commercialization), | addressable market, | • |
| | | | | Department of | serviceable | |
| | | | | Sociology, | addressable market | |
| | | | | Texas A&M | and serviceable | |

| | Τ | I | ı | | | 1 |
|---|-------------------|--------|----------|--------------------|------------------------|------------------|
| | | | | University | obtainable market. | |
| | | | | | 3. Describe the | |
| | | | | | importance of market | |
| | | | | | analysis during needs | |
| | | | | | screening | |
| | Team based | 2 | | | Teams will be | |
| | learning | hours | | | expected to do | |
| | | | | | market analysis for | |
| | | | | | their product | |
| | Opportunity | 1 hour | 09/08/20 | Connie Coulomb, | 1. Describe | |
| 1 | recognition: | 111001 | 03/00/20 | MBA | competition analysis | |
| _ | _ | | | | • | |
| | Competition | | | Managing Partner | and its importance in | |
| | analysis | | | and Consultant, | needs screening. 2 | |
| | | | | Coulomb Strategy | Explain product | |
| | | | | Consulting | differentiation. | |
| | Team based | 2 | | | Teams will be | |
| | learning | hours | | | expected to do | |
| | | | | | competition analysis | |
| | | | | | and product | |
| | | | | | differentiation for | |
| | | | | | their products | |
| | Choosing IP | 1 hour | 09/15/20 | Michael Sharer, | Describe different | Quiz 1 |
| 2 | strategy | 111001 | 03/13/20 | Ph.D. | types of patents. 2. | Quiz 1 |
| _ | Strategy | | | Associate Vice | Explain the | |
| | | | | | | |
| | | | | President for | importance of | |
| | | | | Commercialization, | protecting your | |
| | | | | School of | invention. 3. Identify | |
| | | | | Innovation, | mistakes that can | |
| | | | | Texas A&M | destroy a company's | |
| | | | | University | intellectual property. | |
| | | | | | 4. Describe the | |
| | | | | | process of licensing | |
| | | | | | intellectual property | |
| | | | | | from a university | |
| | Team based | 2 | | | Teams will be | |
| | learning | hours | | | expected to | |
| | learning | Hours | | | determine patent | |
| | | | | | • | |
| | | | | | landscape around | |
| | | | | | their therapeutic | |
| | | | | | product and whether | |
| | | | | | the patents can be | |
| | | | | | licensed. | |
| 7 | Legal | 1 hour | 09/22/20 | Andrew Strong, | 1. Describe the type | <u>Team</u> |
| 2 | considerations | | | J.D. | of entities one can | assignment |
| | for life sciences | | | Partner, | choose from when | <u>2:</u> |
| | startups | | | Pillsbury Winthrop | starting a company. | — Proprietary |
| | - | | | Shaw Pittman LLP | 2. Identify steps to | strategy |
| | | | | | incorporating a | summary |
| | | | | | company. 3. Describe | Sammary |
| | | | | | different types of | |
| | | | | | stocks. | |
| | Toom based | 2 | | | Teams will be | |
| | Team based | 2 | | | | |
| | learning | hours | | | expected to identify | |
| | | | | | value building | |
| | | | | | milestones and the | |

| | | | | | company velvetice | 1 |
|---|-----------------|--------|----------|--------------------|-------------------------|--------|
| | | | | | company valuation | |
| | | | | | when those | |
| | | - • | / / | | milestones are met | |
| 2 | Structures and | 1 hour | 09/29/20 | Andrew Strong, | 1. Describe the | |
| 5 | business models | | | J.D. | general structure of a | |
| | of biotech | | | Partner, | startup. 2. Describe | |
| | startups | | | Pillsbury Winthrop | the role of founders, | |
| | | | | Shaw Pittman LLP | employees, board of | |
| | | | | | directors, and | |
| | | | | | scientific board of | |
| | | | | | advisors in a startup. | |
| | Team based | 2 | | | Teams will be | |
| | learning | hours | | | expected to identify | |
| | Ü | | | | board members, | |
| | | | | | scientific advisors and | |
| | | | | | mentors. Teams will | |
| | | | | | also determine the | |
| | | | | | number of shares for | |
| | | | | | board members and | |
| | | | | | scientific advisors as | |
| | | | | | compensation. | |
| | Coulty store | 1 hour | 10/06/20 | Atul Varadhasham | 1. Explain different | Oui- 2 |
| 2 | Early stage | 1 nour | 10/06/20 | Atul Varadhachary, | · | Quiz 2 |
| 3 | financing | | | M.D., Ph.D. | options for funding | |
| | | | | Managing Partner, | early stage startups. | |
| | | | | Fannin Innovation | 2. Differentiate | |
| | | | | Studio | between dilutive and | |
| | | | | | non-dilutive funding. | |
| | | | | | 3. Create a cap-table. | |
| | | | | | 4. Explain pre-VC | |
| | | | | | financing and typical | |
| | | | | | financing terms. | |
| | Team based | 2 | | | Teams will be | |
| | learning | hours | | | expected to identify | |
| | | | | | government agencies | |
| | | | | | for potential | |
| | | | | | SBIR/STTR funding | |
| | | | | | opportunities | |
| | | | | | relevant to their topic | |
| | | | | | areas. Teams will | |
| | | | | | discuss aims for their | |
| | | | | | SBIR/STTR grants | |
| | Writing a | 1 hour | 10/13/20 | Caleb Holt | 1. Describe a business | |
| 3 | business plan | | | Founder and CEO, | plan. 2. | |
| | · | | | Axle Box | Identify different | |
| | | | | Innovations | elements of a | |
| | | | | | business plan. 2. | |
| | | | | | Describe different | |
| | | | | | exit strategies for a | |
| | | | | | startup. | |
| | Team based | 2 | | | Teams will be | |
| | learning | hours | | | expected to | |
| | icarriing | Hours | | | determine price for | |
| | | | | | - | |
| | | | | | their therapeutic | |
| | | | | | products and an exit | |
| | | | | | strategy | |

| 4 | Regulatory strategy | 1 hour | 10/20/20 | Sean O'Connor, Ph.D., RAC Director, Investigational New Drug Office, MD Anderson Cancer Center | 1. Identify regulatory pathways for drug approval. 2. Describe the process of IND filing. 3. Describe various expedited programs available through FDA for drug approval. | Team assignment 3: Executive summary of a business plan |
|---|------------------------|--------------|----------|---|---|--|
| | Team based learning | 2 hours | | | Teams will expected to determine a path for FDA approval for their therapeutic products | |
| 4 | Clinical trials | 1 hour | 10/27/20 | Rick Silva, Ph.D., MBA Executive Director Clinical Translational Industry Collaborations, Texas A&M Health Science Center | 1. Explain the different phases of clinical trials. 2. Describe different designs of a clinical trial. 3. Describe how a wrong clinical trial can derail a company. | Team assignment 4: Describe a regulatory strategy for the teams' product and rationale for the strategy. |
| | Team based learning | 2 hours | | | Teams will be expected to develop a clinical trial strategy for their products (number of patients, will product be tested with standard of care, clinical trial sites) | 3, |
| | Team presentations | 1-2 hours | 11/03/20 | | | |

Americans with Disabilities Act (ADA)

Texas A&M University is committed to providing equitable access to learning opportunities for all students. If you experience barriers to your education due to a disability or think you may have a disability, please contact Disability Resources in the Student Services Building or at (979) 845-1637 or visit http://disability.tamu.edu. Disabilities may include, but are not limited to attentional, learning, mental health, sensory, physical, or chronic health conditions. All students are encouraged to discuss their disability related needs with Disability Resources and their instructors as soon as possible.

Academic Integrity

For additional information please visit: http://aggiehonor.tamu.edu

"An Aggie does not lie, cheat, or steal, or tolerate those who do."